In this article, we will take a detailed look at High Growth Canadian Stocks to Buy.
For more than a decade, U.S. equities have dominated global markets, but that leadership has begun to soften in 2025. Valuation gaps highlight the shift: U.S. stocks ended 2024 trading roughly 54% above global peers, a premium that narrowed to about 42% by mid-April. History shows that market leadership rotates over time, and the current U.S.-led cycle, which began after the Global Financial Crisis, has already lasted longer than most, raising questions about how sustainable that dominance will be.
The U.S. advantage has traditionally rested on stronger growth, higher corporate profitability, and investor confidence, yet these pillars face increasing pressure from policy uncertainty, moderating consumer sentiment, and rising geopolitical risks. Forward-looking estimates from J.P. Morgan suggest developed international markets could outperform U.S. equities over the next decade, with projected annual returns of 8.1% for EAFE markets versus 6.7% for the U.S. While not forecasts, these assumptions reflect valuation rebalancing and shifting earnings dynamics that favor non-U.S. exposure.
For investors seeking diversification, Canadian equities offer a compelling way to reduce reliance on U.S. mega-cap concentration while gaining exposure to different economic drivers, including commodities, financials, infrastructure, and energy. Canada’s market structure can help balance portfolios during periods of U.S. volatility, and currency movements may further enhance returns if the U.S. dollar weakens. Adding Canadian stocks alongside other global holdings can smooth long-term performance and provide access to resilient, cash-generative businesses that benefit from distinct policy and economic cycles.
With this context in mind, we have compiled a list of 10 high-growth Canadian stocks to buy. From e-commerce to precious metals and cannabis to cryptocurrency, these stocks belong to a range of industries.
Stocks
Our Methodology
For this article, we used the Finviz stock screener to compile a list of the top Canadian stocks. We then selected 10 stocks that had a revenue growth of over 20% in the past five years. The stocks are ranked in ascending order of their revenue growth. We also included the hedge fund sentiment for each stock, which was sourced from Insider Monkey’s database, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 High Growth Canadian Stocks To Buy
9. Draganfly Inc. (NASDAQ:DPRO)
5-year Revenue Growth: 35.71%
Number of Hedge Fund Holders: 6
As of January 15, analyst sentiment remains constructive about Draganfly Inc. (NASDAQ:DPRO), with Northland analyst Michael Latimore initiating coverage on the company with an Outperform rating and a $20 price target. Latimore emphasized strong global and North American demand for intelligent drone systems, noting that Draganfly’s open-architecture platforms and deep industry experience position it well for large procurement programs. He expects this demand to translate into significant growth, estimating that company revenue could more than double annually in 2026 and 2027 as programs scale.
During Draganfly’s 2025 Q3 earnings call, the company reported revenue of $2.155 million, representing a 14.4% year-over-year increase, alongside continued momentum in defense, public safety, and enterprise markets. The company strengthened its military and government positioning through new leadership appointments, a collaboration with Paladin AI, and a notable order from the U.S. Army. Draganfly Inc. (NASDAQ:DPRO) also expanded its commercial footprint through partnerships with Drone Nerds, Global Ordinance, and a Fortune 50 telecom company, broadening distribution and reinforcing its global market presence.
Operationally, Draganfly Inc. (NASDAQ:DPRO) announced the deployment of its drones integrated with Smith Myers’ ARTEMIS Mobile Phone Detection & Location System for search-and-rescue missions, beginning with SAR Sweden. Management highlighted the rapid integration and flexibility of these platforms, positioning them for a wide range of demanding operational roles across public safety and emergency response, and reinforcing the company’s focus on mission-critical, life-saving applications.
Headquartered in Saskatoon, Canada, Draganfly Inc. (NASDAQ:DPRO) is a leading developer of drone solutions and systems with more than 22 years of experience delivering advanced drones, software platforms, and AI-driven technologies.
8. Cronos Group Inc. (NASDAQ:CRON)
5-year Revenue Growth: 37.71%
Number of Hedge Fund Holders: 16
On January 14, a Bernstein analyst reiterated a Hold rating on Cronos Group Inc. (NASDAQ:CRON) and maintained a price target of $2.30, in line with the broader analyst consensus, which also stands at Hold with the same target. Despite the neutral outlook, Cronos continues to stand out for its exceptionally strong balance sheet, carrying no debt and holding approximately $824 million in cash, cash equivalents, and short-term investments—one of the most robust liquidity positions in the cannabis industry.
During its third-quarter 2025 earnings call, Cronos reported a record quarter, posting consolidated net revenue of $36.3 million, representing a 6% increase year over year. Performance was driven in part by the continued strength of the Spinach brand, which has become one of Canada’s leading cannabis brands with a 4.5% overall market share and particularly strong traction in the edibles and vape categories. Cronos Group Inc. (NASDAQ:CRON) also announced the completion of its Phase 2 expansion at GrowCo, a development expected to ease flower supply constraints and support additional growth momentum in 2026.
Cronos Group Inc. (NASDAQ:CRON) is a globally diversified, vertically integrated cannabis company with operations spanning four continents. The company owns and operates Canadian licensed production facilities, regulated under Health Canada’s framework for medical cannabis production.
